Stifel Nicolaus analyst Justin Keywood assigned a Buy rating to Greenbrook Tms (GBOKF) today and set a price target of C$3.00. The company’s shares closed last Monday at $1.10, close to its 52-week low of $0.89.
According to TipRanks.com, Keywood is ranked #2294 out of 6616 analysts.
Greenbrook Tms has an analyst consensus of Strong Buy, with a price target consensus of $2.72.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.48 and a one-year low of $0.89. Currently, Greenbrook Tms has an average volume of 4,510.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Greenbrook Tms, Inc. engages in the provision of transcranial magnetic stimulation, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder. It operates through Outpatient Mental Health Service Centers segment. The company was founded on February 9, 2018 and is headquartered in Toronto, Canada.
